Observational Study
Copyright ©The Author(s) 2023.
World J Gastrointest Surg. May 27, 2023; 15(5): 917-930
Published online May 27, 2023. doi: 10.4240/wjgs.v15.i5.917
Table 1 Baseline index data of hepatocellular carcinoma patients undergoing association liver partition and portal vein ligation for staged hepatectomy
Variable
ALPPS, n = 37
Age, yr45 (26-75)
Sex, women/man, n (%)3 (8.1)/34 (91.9)
BMI, kg/m222.2 (17.99-30.09)
AFP, ≥ 400 ng/mL/< 400 ng/mL, n (%)19 (51.4)/18 (48.6)
Degree of liver fibrosis, n
No fibrosis7
Mild fibrosis2
Moderate fibrosis/fibrosis8
Cirrhosis, n (%)20 (54.1)
MELD score5.12 (0.75-11.00)
ICGR15, %5.3 (1.3-18.8)
Child-Pugh class, A/B/C, n36/1/0
BCLC staging, A/B/C, n10/7/20
Table 2 Intraoperative and postoperative conditions of association liver partition and portal vein ligation for staged hepatectomy - stage 1 and 2
Variable
ALPPS - stage 1
ALPPS - stage 2
Operative time, min341 (229-496)300 (167-483)
Blood loss, mL328 (50-2600)792 (200-6000)
Blood transfusion, mL300 (0-900)250 (0-2150)
Postoperative bile leakage, n
No3627
Yes13
Clavien-Dindo classification, n
I2012
II1414
III34
IV00
ISGLS classification, n
A219
B1618
C01
Ishak fibrosis score/3 (1-6)
Ishak inflammation score/5 (2-12)
Table 3 The proportion of CD4+CD25+ regulatory T cells to CD4+ T cells before and after the association liver partition and portal vein ligation for staged hepatectomy - stage 1 and 2
ALPPS
PRE
POD1
POD3
POD5
POD7
POD10
F
P value
ALPPS-11.69 ± 1.321.79 ± 1.422.29 ± 1.342.41 ± 1.492.62 ± 1.722.64 ± 1.646.9620.001
ALPPS-21.69 ± 1.322.19 ± 1.262.28 ± 1.632.73 ± 2.052.21 ± 1.492.34 ± 1.354.7260.011
Table 4 Data related to liver volume, including standard liver volume, future liver remnant, future liver remnant/standard liver volume ratio, and future liver remnant increase
Variable
ALPPS stage 1 and 2
SLV, cm31034.0 (851.9-1300.7)
Preoperation of ALPPS-1
FLR, cm31043.3 (851.8-1358.2)
FLR/SLV, %35.1 (18.9-47.4)
Preoperation of ALPPS-2
FLR, cm3548.4 (378.1-823.0)
FLR/SLV, %53.2 (33.8-78.3)